Immunotherapy in Cancer Management: A Literature Review of Clinical Efficacy of Pembrolizumab in the Non-small Cell Lung Cancer Treatment

Luísa Biscaglia Miquelotti ¹ , Marcel Henrique Marcondes Sari ² , Luana Mota Ferreira ^1,3 *

Cited by CrossRef: 1

1- Staropoli N, Salvino A, Falcone F, Farenza V, Costa M, Rossini G, Manti F, Crispino A, Riillo C, Ciliberto D, Arbitrio M, Tassone P, Tagliaferri P. Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity. Front Oncol. 2023;13 [Crossref]

2- Balachandran D, Bashoura L, Sheshadri A, Manzullo E, Faiz S. The Impact of Immunotherapy on Sleep and Circadian Rhythms in Patients with Cancer. Front Oncol. 2023;13 [Crossref]

3- Ma M, Li L, Yang S, Huang C, Zhuang W, Huang S, Xia X, Tang Y, Li Z, Zhao Z, Chen Q, Qiao G, Lian Z. Lymphatic endothelial cell-mediated accumulation of CD177 + Treg cells suppresses antitumor immunity in human esophageal squamous cell carcinoma . OncoImmunology. 2024;13(1) [Crossref]